Wedbush Maintains Outperform Rating on Kiniksa Pharmaceuticals, Keeps $102 Target

Wedbush maintained its Outperform rating on Kiniksa Pharmaceuticals and set a $102 price target. The target implies 14.3% upside from the Oct. 27 close of $89.20.